MAPT and tauopathy: As the human tissue was from a donor with late-stage disease, it is possible that our MAPT KI mutant mice would develop seed-competent tau with further aging; however, our results from RT-QuIC and MC1 staining at more advanced age suggest that this will not be the case, indicating a limitation of the mice which should be considered to best model the earliest stages of tauopathy.